Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talaporfin sodium (Light Sciences Oncology)
- Development stage
- Unknown
- Lead developer
- Light Sciences Oncology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Talaporfin sodium is a second-generation, water-soluble chlorin-based photosensitizer used in photodynamic therapy (PDT). Developed by Light Sciences Oncology as part of the Litx platform, the drug is administered intravenously and subsequently activated by low-intensity light from percutaneously implanted interstitial light-emitting diodes (LEDs). This activation triggers the production of singlet oxygen and other reactive oxygen species, which induce localized tumor cell apoptosis and microvascular shutdown. The primary clinical focus for Light Sciences Oncology was the treatment of unresectable hepatocellular carcinoma (HCC), where it was evaluated in a Phase 3 trial (NCT00389389) against standard-of-care therapies like TACE and RFA. However, development by the company was halted following financial difficulties and the termination of its pivotal trials. The drug remains approved in Japan for the treatment of certain cancers, such as glioma and esophageal cancer, under the brand name Laserphyrin.
- Brand names
- LitxLaserphyrinAptocine
- Other names
- mono-L-aspartyl chlorin e6NPe6NPe-6NPe 6talaporfin
Beyond the preview
Go deeper on talaporfin sodium (Light Sciences Oncology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talaporfin sodium (Light Sciences Oncology).